<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="252">
  <!-- This xml conforms to:  http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>Information obtained from ClinicalTrials.gov on October 20, 2011</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01209286</url>
  </required_header>
  <id_info>
    <org_study_id>MT103-206</org_study_id>
    <nct_id>NCT01209286</nct_id>
  </id_info>
  <brief_title>Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)</brief_title>
  <official_title>An Open Label, Multicenter, Exploratory Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab in Adult Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Micromet GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Micromet GmbH</source>
  <oversight_info>
    <authority>Germany: Paul-Ehrlich-Institut</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the bispecific T-cell engager blinatumomab
       (MT103) is effective, safe and tolerable in the treatment of patients with
      relapsed/refractory B-precursor ALL.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Relapsed/refractory B-precursor ALL in adult patients is an aggressive malignant disease
      with dismal prognosis and unmet medical need. Additional therapeutic approaches are urgently
      needed. Blinatumomab is a bispecific single-chain antibody construct designed to link B
      cells and T cells resulting in T cell activation and a cytotoxic T cell response against
      CD19 expressing cells. The purpose of this study is to investigate the efficacy, safety and
      tolerability of two doses of the bispecific T-cell engager blinatumomab (MT103) in adult
      patients with relapsed/refractory B-precursor ALL. Patients will receive up to five 4-week
      cycles of intravenous blinatumomab treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2010</start_date>
  <primary_completion_date type="Anticipated">March 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of patients with Complete Remission (CR/CRh*)</measure>
    <time_frame>within 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with Minimal Residual Disease (MRD) response</measure>
    <time_frame>within 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to hematological relapse</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and severity of adverse events</measure>
    <time_frame>within 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>B-ALL</condition>
  <arm_group>
    <arm_group_label>Blinatumomab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Blinatumomab</intervention_name>
    <description>15µg/m2/day blinatumomab c.i.v.</description>
    <arm_group_label>Blinatumomab</arm_group_label>
    <other_name>MT103</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Blinatumomab</intervention_name>
    <description>30µg/m2/day blinatumomab c.i.v.</description>
    <arm_group_label>Blinatumomab</arm_group_label>
    <other_name>MT103</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with B-precursor ALL relapsed after at least induction and consolidation or
             having refractory disease

          -  More than 5% blasts in bone marrow

          -  ECOG performance status ≤ 2

          -  Life expectancy of ≥ 12 weeks

        Exclusion Criteria:

          -  History or presence of clinically relevant CNS pathology

          -  Infiltration of cerebrospinal fluid (CSF) by ALL

          -  Autologous/allogeneic HSCT within six weeks/three months prior to start of
             blinatumomab treatment

          -  Active Graft-versus-Host Disease (GvHD)

          -  Patients with Ph+ ALL eligible for treatment with dasatinib or imatinib

          -  Cancer chemotherapy within two weeks prior to start of blinatumomab treatment

          -  Immunotherapy (e.g. rituximab) within four weeks prior to start of blinatumomab
             treatment

          -  Infection with HIV or hepatitis B (HBsAg positive) or hepatitis C virus  (anti-HCV
             positive)

          -  Pregnant or nursing women

          -  Previous treatment with blinatumomab
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Max Topp, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universität Würzburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gerhard Zugmaier, MD</last_name>
    <phone>+49-89-895277</phone>
    <phone_ext>367</phone_ext>
    <email>clinicaltrials@micromet.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Petra Klappers</last_name>
    <email>clinicaltrials@micromet.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Würzburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <lastchanged_date>October 10, 2011</lastchanged_date>
  <firstreceived_date>September 23, 2010</firstreceived_date>
  <responsible_party>
  </responsible_party>
  <keyword>Blinatumomab</keyword>
  <keyword>B-ALL</keyword>
  <keyword>adult ALL</keyword>
  <keyword>relapsed ALL</keyword>
  <keyword>refractory ALL</keyword>
  <keyword>Leukemia</keyword>
  <keyword>ALL</keyword>
  <keyword>Lymphatic diseases</keyword>
  <keyword>Lymphoproliferative disorders</keyword>
  <keyword>bispecific antibody</keyword>
  <keyword>anti-CD19</keyword>
  <keyword>Immunotherapeutic treatment</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Bispecific</mesh_term>
  </intervention_browse>
</clinical_study>
